620 related articles for article (PubMed ID: 28228105)
1. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
[TBL] [Abstract][Full Text] [Related]
2. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
3. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
4. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
5. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
[TBL] [Abstract][Full Text] [Related]
6. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
Hong R; Zhou Y; Tian X; Wang L; Wu X
Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
[TBL] [Abstract][Full Text] [Related]
8. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells.
Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M
J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363
[TBL] [Abstract][Full Text] [Related]
9. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
[TBL] [Abstract][Full Text] [Related]
10. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL
Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972
[TBL] [Abstract][Full Text] [Related]
11. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.
Yang Y; Zhang X; Lin F; Xiong M; Fan D; Yuan X; Lu Y; Song Y; Zhang Y; Hao M; Ye Z; Zhang Y; Wang J; Xiong D
J Hematol Oncol; 2019 Apr; 12(1):46. PubMed ID: 31023384
[TBL] [Abstract][Full Text] [Related]
12. Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
Duell J; Lukic DS; Karg M; Reusch U; Koch J; Zhukovsky EA; Rajkovic E; Treder M; Rasche L; Eisele F; Einsele H; Topp MS
J Immunother; 2019 Jun; 42(5):180-188. PubMed ID: 31090657
[TBL] [Abstract][Full Text] [Related]
13. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
14. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
[TBL] [Abstract][Full Text] [Related]
15. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
[TBL] [Abstract][Full Text] [Related]
16. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
17. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
18. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
[TBL] [Abstract][Full Text] [Related]
19. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
20. CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.
Xu L; Wang S; Li J; Li B
Biochem Biophys Res Commun; 2019 Feb; 509(3):739-745. PubMed ID: 30611570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
